Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer Cells Published
Stockhouse,
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an…
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an…
GlobeNewswire 2016-08-18 MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- (Nasdaq: IMMU ) today announced that adding an inhibitor of ATP-binding…
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ( IMMU ) today announced that adding an inhibitor of…
Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an inhibitor of ATP-binding cassette (ABC) transporters to…
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ( IMMU ) today announced that adding an inhibitor of…
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ( IMMU ) today announced that adding an inhibitor of…
MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an…